Probiotics in cirrhosis: do we expect too much?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Liver international (Print)

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/liv.12288PMID 24099262
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An update on the use and investigation of probiotics in health and disease

  2013cited by this paper
• Gut microbiota and hepatic encephalopathy

  2013cited by this paper
• Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial

  2013cited by this paper
• Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications

  2013cited by this paper
• VSL#3® probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis

  2013cited by this paper
• An Open Label Randomised Controlled Trial of Probiotics for Primary Prophylaxis of Hepatic Encephalopathy in Patients with Cirrhosis

  2013cited by this paper
• Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study

  2012cited by this paper
• Lactobacillus johnsonii La1 without antioxidants does not decrease bacterial translocation in rats with carbon tetrachloride-induced cirrhosis

  2012cited by this paper
• Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial

  2012cited by this paper
• Lactobacillus johnsonii La1 without antioxidants does not decrease bacterial translocation in rats with carbon tetrachloride-induced cirrhosis.

  2012cited by this paper
• Probiotics in hepatology.

  2011cited by this paper
• Probiotics for patients with hepatic encephalopathy.

  2011cited by this paper
• Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open-Label, Randomized Controlled Trial of Lactulose, Probiotics, and No Therapy

  2010cited by this paper
• Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy

  2010cited by this paper
• Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study

  2009cited by this paper
• VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet‐induced nonalcoholic steatohepatitis model in mice

  2009cited by this paper
• Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.

  2008cited by this paper
• An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy

  2008cited by this paper
• Probiotic Prophylaxis in Predicted Severe Acute Pancreatitis: A Randomised, Double-Blind, Placebo-Controlled Trial.

  2008cited by this paper
• Probiotic Yogurt for the Treatment of Minimal Hepatic Encephalopathy

  2008cited by this paper
• Review article: probiotics in gastrointestinal and liver diseases

  2007cited by this paper
• Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis

  2006cited by this paper
• Bacterial translocation and its consequences in patients with cirrhosis

  2005cited by this paper
• Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases

  2005cited by this paper
• Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis

  2004cited by this paper
• Effect of Lactobacillus-Fermented Diets on Bacterial Translocation and Intestinal Flora in Experimental Prehepatic Portal Hypertension

  2003cited by this paper
• Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis.

  2002cited by this paper
• Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis

  1999cited by this paper
• randomised double blind placebo controlled trial

  year unknowncited by this paper

• New insights into gut-liver axis in advanced liver diseases: A promising therapeutic target.

  2025cites this paper
• Novel Therapies in Hepatic Encephalopathy.

  2020cites this paper
• Protective Effect of Probiotics against Esophagogastric Variceal Rebleeding in Patients with Liver Cirrhosis after Endoscopic Therapy

  2020cites this paper
• Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized Trial

  2019cites this paper
• Probiotics for people with hepatic encephalopathy.

  2017cites this paper